Marshall Wace
BBIO icon

Marshall Wace’s BridgeBio Pharma BBIO Stock Holding History

Marshall Wace’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Sell
275,516
-58,866
-18% -$4.12M 0.02% 717
2026
Q1 		$24.8M Buy
334,382
+259,696
+348% +$18.8M 0.02% 619
2025
Q4 		$5.71M Sell
74,686
-26,556
-26% -$1.74M 0.01% 1094
2025
Q3 		$5.26M Sell
101,242
-321,473
-76% -$15.7M 0.01% 1164
2025
Q2 		$18.3M Buy
422,715
+856
+0.2% +$31.1K 0.02% 621
2025
Q1 		$14.6M Sell
421,859
-406,099
-49% -$13.7M 0.02% 624
2024
Q4 		$22.7M Sell
827,958
-5,278
-0.6% -$136K 0.03% 497
2024
Q3 		$21.2M Buy
833,236
+802,387
+2,601% +$21.1M 0.03% 494
2024
Q2 		$781K Buy
+30,849
New +$843K ﹤0.01% 1790
2024
Q1 		– Sell
-37,897
Closed -$1.53M – 2433
2023
Q4 		$1.53M Sell
37,897
-125,019
-77% -$3.75M ﹤0.01% 1335
2023
Q3 		$4.3M Buy
+162,916
New +$4.62M 0.01% 933
2023
Q2 		– Sell
-1,084,595
Closed -$18M – 2464
2023
Q1 		$18M Buy
+1,084,595
New +$12.6M 0.04% 503
2022
Q4 		– Sell
-71,245
Closed -$708K – 2932
2022
Q3 		$708K Buy
+71,245
New +$740K ﹤0.01% 2575
2022
Q1 		– Sell
-290,362
Closed -$4.84M – 3351
2021
Q4 		$4.84M Buy
290,362
+274,843
+1,771% +$11.6M 0.01% 1378
2021
Q3 		$727K Buy
+15,519
New +$832K ﹤0.01% 2201
2021
Q2 		– Sell
-75,995
Closed -$4.68M – 2651
2021
Q1 		$4.68M Buy
+75,995
New +$4.97M 0.02% 877

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marshall Wace's BBIO Position: Q2 2026 in Review

Marshall Wace reduced its BridgeBio Pharma (BBIO) stake by 18% in Q2 2026, selling an estimated $4.12M and leaving 275,516 shares worth $20.5M. The position accounts for 0.02% of the portfolio, ranked #717.

Marshall Wace first reported a position in BBIO in Q1 2021 and has held it in 16 quarters since. The position peaked at $24.8M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Marshall Wace held 275,516 shares of BridgeBio Pharma worth $20.5M as of Q2 2026.
  • Marshall Wace sold 58,866 BridgeBio Pharma shares in Q2 2026, an estimated $4.12M.
  • BridgeBio Pharma made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #717 holding.
  • Marshall Wace first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 16 quarters since.
  • Marshall Wace's BridgeBio Pharma position peaked at $24.8M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.